Application of antisense technology to urologic cancers.
Antisense oligodeoxynucleotides (ODNs) inhibit target gene expression and are applicable to human diseases including malignancies. Although improvements in ODNs and cellular delivery systems are needed, antisense ODNs hold great promise as a new class of therapeutic agents.
Tomita
Y
Y
Department of Urology, Niigata University Faculty of Medicine, Asahimachi, Niigata, Japan. ytomita@med.niigata-u.ac.jp
D017209:Apoptosis / Q000235:genetics; D019254:Genes, bcl-2; D006801:Humans; D020935:MAP Kinase Signaling System / Q000502:physiology; D015394:Molecular Structure; D020319:Oligodeoxyribonucleotides, Antisense / Q000235:genetics / Q000627:therapeutic use*; D014571:Urologic Neoplasms / Q000235:genetics* / Q000628:therapy*
D020319:Oligodeoxyribonucleotides, Antisense